This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| 5-Amino-1MQ | ATX-304 | |
|---|---|---|
| Highest evidence tier on the page | E4 Preclinical only Animal or in vitro work. Not demonstrated in humans. | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. |
| Regulatory status | Not approved for human use | Not stated |
| Research area | Metabolic and incretin | Metabolic and incretin |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | C10H11N2+ (free cation); C10H11ClN2 (chloride salt) | C16H11Cl2N3O2S |
| Molar mass | 159.21 g/mol, calculated for the free cation; 194.66 g/mol, calculated for the chloride salt | ≈380.25 g/mol |
| CAS number | 685079-15-6 (free cation); no independently confirmed CAS number exists for the chloride salt | 1261289-04-6 |
| Registered trials on this site | None linked yet | None linked yet |
| What is not known | Everything about this compound in a human being. No interventional trial, observational study or published case report of 5-Amino-1MQ administered to a person exists, so whether it has any effect, at any dose, with any safety profile, in a human is entirely unanswered. Any human... | The exact dose, frequency, and duration used in the published 2018 human Phase IIa proof-of-concept trial; those details were not obtainable from the abstract-level source reviewed for this entry. The current status of any newer Amplifier Therapeutics clinical trial. Industry press from 2023 describes a... |
Full pages: 5-Amino-1MQ and ATX-304. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
